These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 25798937)

  • 1. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.
    Mailly L; Xiao F; Lupberger J; Wilson GK; Aubert P; Duong FHT; Calabrese D; Leboeuf C; Fofana I; Thumann C; Bandiera S; Lütgehetmann M; Volz T; Davis C; Harris HJ; Mee CJ; Girardi E; Chane-Woon-Ming B; Ericsson M; Fletcher N; Bartenschlager R; Pessaux P; Vercauteren K; Meuleman P; Villa P; Kaderali L; Pfeffer S; Heim MH; Neunlist M; Zeisel MB; Dandri M; McKeating JA; Robinet E; Baumert TF
    Nat Biotechnol; 2015 May; 33(5):549-554. PubMed ID: 25798937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.
    Mailly L; Wrensch F; Heydmann L; Fauvelle C; Brignon N; Zeisel MB; Pessaux P; Keck ZY; Schuster C; Fuerst TR; Foung SKH; Baumert TF
    Antiviral Res; 2019 Feb; 162():136-141. PubMed ID: 30599173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
    Colpitts CC; Tawar RG; Mailly L; Thumann C; Heydmann L; Durand SC; Xiao F; Robinet E; Pessaux P; Zeisel MB; Baumert TF
    Gut; 2018 Apr; 67(4):736-745. PubMed ID: 28360099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Claudin 1 as a target for anti-hepatitis C virus strategy].
    Fukasawa M
    Yakugaku Zasshi; 2014; 134(5):635-40. PubMed ID: 24790046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.
    Fofana I; Krieger SE; Grunert F; Glauben S; Xiao F; Fafi-Kremer S; Soulier E; Royer C; Thumann C; Mee CJ; McKeating JA; Dragic T; Pessaux P; Stoll-Keller F; Schuster C; Thompson J; Baumert TF
    Gastroenterology; 2010 Sep; 139(3):953-64, 964.e1-4. PubMed ID: 20685314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-hepatitis C virus strategy targeting host entry factor claudin-1].
    Fukasawa M
    Uirusu; 2015; 65(2):245-254. PubMed ID: 27760923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis: Tightening the grip on clearing HCV infection.
    Ray K
    Nat Rev Gastroenterol Hepatol; 2015 May; 12(5):249. PubMed ID: 25850009
    [No Abstract]   [Full Text] [Related]  

  • 8. Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.
    Fukasawa M; Nagase S; Shirasago Y; Iida M; Yamashita M; Endo K; Yagi K; Suzuki T; Wakita T; Hanada K; Kuniyasu H; Kondoh M
    J Virol; 2015 May; 89(9):4866-79. PubMed ID: 25673725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein.
    Sautto GA; Wisskirchen K; Clementi N; Castelli M; Diotti RA; Graf J; Clementi M; Burioni R; Protzer U; Mancini N
    Gut; 2016 Mar; 65(3):512-23. PubMed ID: 25661083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-hepatitis C Virus Strategy Targeting the Entry Steps].
    Fukasawa M
    Yakugaku Zasshi; 2019; 139(1):89-95. PubMed ID: 30606936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model.
    Shimizu Y; Shirasago Y; Kondoh M; Suzuki T; Wakita T; Hanada K; Yagi K; Fukasawa M
    J Virol; 2018 Apr; 92(8):. PubMed ID: 29437969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly downregulated in hepatocellular carcinoma.
    Sekhar V; Pollicino T; Diaz G; Engle RE; Alayli F; Melis M; Kabat J; Tice A; Pomerenke A; Altan-Bonnet N; Zamboni F; Lusso P; Emerson SU; Farci P
    PLoS Pathog; 2018 Mar; 14(3):e1006916. PubMed ID: 29538454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.
    Paciello R; Urbanowicz RA; Riccio G; Sasso E; McClure CP; Zambrano N; Ball JK; Cortese R; Nicosia A; De Lorenzo C
    J Gen Virol; 2016 Jan; 97(1):82-94. PubMed ID: 26519290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanding the Host Range of Hepatitis C Virus through Viral Adaptation.
    von Schaewen M; Dorner M; Hueging K; Foquet L; Gerges S; Hrebikova G; Heller B; Bitzegeio J; Doerrbecker J; Horwitz JA; Gerold G; Suerbaum S; Rice CM; Meuleman P; Pietschmann T; Ploss A
    mBio; 2016 Nov; 7(6):. PubMed ID: 27834208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mice Expressing Minimally Humanized CD81 and Occludin Genes Support Hepatitis C Virus Uptake In Vivo.
    Ding Q; von Schaewen M; Hrebikova G; Heller B; Sandmann L; Plaas M; Ploss A
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
    Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
    J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission.
    Fofana I; Xiao F; Thumann C; Turek M; Zona L; Tawar RG; Grunert F; Thompson J; Zeisel MB; Baumert TF
    PLoS One; 2013; 8(5):e64221. PubMed ID: 23704981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro.
    Fénéant L; Ghosn J; Fouquet B; Helle F; Belouzard S; Vausselin T; Séron K; Delfraissy JF; Dubuisson J; Misrahi M; Cocquerel L
    PLoS One; 2015; 10(11):e0142539. PubMed ID: 26561856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection.
    Liu S; Yang W; Shen L; Turner JR; Coyne CB; Wang T
    J Virol; 2009 Feb; 83(4):2011-4. PubMed ID: 19052094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus depends on E-cadherin as an entry factor and regulates its expression in epithelial-to-mesenchymal transition.
    Li Q; Sodroski C; Lowey B; Schweitzer CJ; Cha H; Zhang F; Liang TJ
    Proc Natl Acad Sci U S A; 2016 Jul; 113(27):7620-5. PubMed ID: 27298373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.